US FDA Device Funding Would Leap By 26% In 2019 Under Trump Budget Proposal

US FDA Device Center program funding would see a $131m increase under the Trump administration's budget proposal, which prioritizes "speeding innovations" in medical devices and other products the agency regulates, and closely examining what regulations need to be revised, updated or eliminated.

FDA entrance sign 2016

A Trump administration budget proposal released Feb. 12 states that budget authority for medical device programs at FDA would rise by $131m in 2019 to $636m, an approximate 26% increase over levels in 2018, when a bevy of continuing resolutions left FDA stuck at 2017 funding levels. As part of that funding, medical device user fee spending would rise by $3m in 2019 – from $193m for 2018 to $197m for 2019 – the Feb. 12 budget document stated.

Overall, FDA's budget authority appropriation would grow by $473m, with much of intended to support getting new devices and drugs...

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Medtech Insight for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required

More from Legislation

More from Policy & Regulation

Remote Regulatory Assessments Become Swiss Army Knife For US FDA’s Oversight Of Facilities

 

“RRAs are valuable oversight tools and under certain circumstances, can assist FDA in its mission to protect public health, oversee regulated industry, and help ensure regulated products comply with FDA requirements,” according to final guidance.

FDA Greenlights Expanded Use Of Boston Scientific’s Pulse Field Ablation System

 

A recent approval from the US FDA allowing Boston Scientific to broaden its labeling for its pulse field ablation system means more patients with one type of AFib will have access to a promising new treatment.

Commission Decision Launches Pediatric And Rare Disease Expert Group

 

A revised annex to the original decision also outlines expert remuneration limits and introduces further changes.